Antimicrobials are a leading cause of severe T cell-mediated adverse drug reactions (ADRs). The purpose of this review is to address the current understanding of antimicrobial cross-reactivity and the ready availability of and evidence for in-vitro, in-vivo, and ex-vivo diagnostics for T cell-mediated ADRs.
INTRODUCTION
T cell-mediated drug hypersensitivities are a group of immune-mediated adverse drug reactions (ADRs) of varying phenotype and severity. Descriptions of antimicrobial-associated T cell-mediated ADRs date back to the use of the first sulfa antimicrobials [1] and then almost a decade later to early preparations of penicillins [2, 3] . These immune-mediated ADRs result in antimicrobial allergy 'labels' that impact patient outcomes and antimicrobial usage [4 && ,5,6 && ]. For the diagnosis of antimicrobial allergy, the use of skin prick testing and intradermal testing (SPT/IDT) remains the mainstay of first-stage diagnosis for immediate reactions suspected to be IgEmediated. This should be followed by an ingestion challenge which, in combination with SPT/IDT, is still considered to be the gold standard [7] . However, in the setting of serious T cell-mediated ADRs, both patch testing, a more established test for the diagnosis of delayed reactions, and SPT/IDT lack the 100% negative predictive value (NPV) necessary to rechallenge patients to drugs either orally or systemically following negative testing [8] . In this review, we will address the current understanding of antimicrobial cross-reactivity and the ready availability of and evidence for immune-mediated ADR in-vitro, in-vivo and ex-vivo diagnostics.
The epidemiology of serious T cell-mediated reactions varies according to the region studied and is driven by genetic predisposition to these reactions. In general, given the high prevalence of antibiotic use, 50% or more of severe cutaneous adverse reactions (SCARs) globally are associated with antimicrobials -commonly penicillins, glycopeptides, and sulfonamide antibiotics -and antiretrovirals [5,9 && ,10 && ]. The most serious of these reactions include Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustolosis (AGEP). Additionally, abacavir, a guanosine analog nucleoside reverse transcriptase inhibitor, is associated with a severe human leukocyte antigen (HLA)-B Ã 57:01-restricted, CD8 þ T cell-mediated hypersensitivity reaction [abacavir hypersensitivity syndrome (AHS)], which is characterized clinically by fever, malaise, gastrointestinal symptoms, and late onset of rash (70%) a median of 8 days after initiation of dosing. In the setting of multiple implicated antimicrobials, the cause of SCARs and other immune-mediated ADRs is often unclear despite application of published causality assessments [11, 12] .
EFFECTOR IMMUNOLOGY OF T CELL-MEDIATED ADVERSE DRUG REACTIONS
Immune-mediated ADRs can be classified by the revised Gell and Coombs classification (Table 1) [13]. This review focuses on type IV, T cell-dependent immune-mediated ADRs. The pathogenesis of T cell-mediated immune responses has been long debated, yet the presence of allergen-specific T lymphocytes is an observation in most drug-allergy reactions. White et al. [4 && ] reviewed the current mechanistic hypotheses of T cell-dependent immune-mediated ADRs namely pharmacological interaction of drugs with immune receptors (the p-i concept), the hapten/prohapten model, and the altered peptide repertoire model (Fig. 1) . The cellular and cytokine response within immunemediated ADRs vary (Table 1) .
Many of the SCARs are known to rely on drugspecific T-cell responses that can persist in the circulation for more than 20 years after drug exposure [60] . Blistering and severe immune-mediated ADRs (SJS/TEN or AHS) are thought to correlate with CD8 þ T-cell infiltration, whereas simple exanthema and DRESS are largely associated with CD4 þ T cells or mixtures of CD4 þ and CD8 þ T cells [61, 62] . In general, cytokines upregulated in immunemediated ADRs are IL-2, IL-5, IL-13, and IFNg [63] . The key immune mediators differ slightly for each immune-mediated ADR phenotype, summarized in Table 1 . An understanding of immune mediators is vital for future works measuring cytokines in ex-vivo T-cell diagnostics.
HISTORICAL APPROACHES TO T CELL-MEDIATED HYPERSENSITIVITIES
Testing for immune-mediated ADRs remains problematic because of both lack of widespread availability and low sensitivity of conventional methods. Many patients with nonspecific rashes or those that occur during the course of an acute infection will not demonstrate reproducible symptoms on future rechallenge. Caubet et al. [64] demonstrated that only 6.8% of patients with a history of antibiotic associated 'rash' had a reproducible phenotype on oral challenge. In recent studies, IDT has been suggested to be more sensitive than patch testing AGEP AGEP -CD4 þ T cells infiltrate, CD8 þ T cells and CXCL8 and GM-CSF. CXCL8 is involved in the chemotaxis of neutrophils; Th17 cells involved [47] [48] [49] [50] ADR, adverse drug reaction; AGEP, acute generalized exanthematous pustolosis; DHR, drug hypersensitivity reaction; DILI, drug-induced liver injury; DRESS, drug reaction with eosinophilia and systemic symptoms; EM, erythema multiforme; FDE, fixed drug eruption; GM-CSF, granulocyte monocyte colony-stimulating factor; HSS, hypersensitivity syndrome; MPE, maculopapular exanthema; ND, no data; NK, natural killer; PMN, polymorphonuclear cell; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; T reg , regulatory T cell. a Not classically described by Gell and Coombs criteria of T cell-mediated hypersensitivity. b MPE, otherwise known as 'morbilliform' drug eruption, is the most commonly reported antibiotic-associated T cell-mediated ADR. c DILI -DILI will not be covered in detail in this review, as the mechanism can be dose dependent/predictable or unpredictable. The unpredictable reactions may in fact be immune-mediated or metabolic in origin. T lymphocytes secreting granzyme B have been noted on liver biopsy. CD4 þ /CD8 þ T cells secreting IL-13 and IFNg have been detected in serum from in patients with DILI. The most commonly implicated antimicrobials are amoxicillin-clavulanate and flucloxacillin, in particular in those with HLA-B Ã 57:01. Reproduced with permission from [13].
Patch testing
The specificity of patch testing for SCARs has been high in settings where drug concentrations have been validated against negative controls. The sensitivity of patch testing varies, however, and is highest for DRESS (32-80%) [112, 113] and AGEP (58-64%) [112, 114] , and lowest for SJS/TEN (9-24%) [112, 114] and maculopapular examthem (MPE) (10-40%) [65, 113] . Patch testing lacks an appropriate positive control and results may be difficult to interpret in patients who are on immunosuppressants that impact T cell-mediated immunity. For antibiotics, patch testing to the upper back is generally recommended 6 weeks to 6 months after skin healing [115] . In a multicenter study of patch testing in SCARs, Barbaud et al. [112] demonstrated that patch testings were most frequently positive for b-lactams (primarily amoxicillin) and pristinamycin. Buonomo et al. [116] demonstrated patch testing's utility in immune-mediated ADRs, predominately cephalosporin-associated MPE, in a retrospective cohort. Barbaud et al. [66] utilized patch testing in 29 cases of pristinamycin-associated immune-mediated ADRs, with a higher than expected sensitivity noted (69%). In 27 patients with oral challenge confirmed fixed drug eruption (FDE) to trimethoprim-sulfamethoxazole (TMP-SMX), 93% sensitivity for patch testing was demonstrated [117] .
However, in a recent study by Andrade et al. [118] 0% (0/15) of FDE were positive on patch testing. The utility of patch testing in immune-mediated ADRs caused by quinolones and TMP-SMX is notoriously poor [112, 119, 120] . Patch testing has been demonstrated to be effective in a small number of antibiotic-associated SJS/TEN [114, [121] [122] [123] , AGEP [70, 112, 120, 124, 125] , FDE [126] [127] [128] , DRESS [112, 129] , MPE [130] , and erythema multiforme [131] case series. To date, success with patch testing in cases of suspected antiretroviral hypersensitivity has been limited to abacavir. Patch testing for abacavir showed 100% specificity and 87% diagnostic sensitivity when used as an adjunctive test to define true AHS [8, 132] .
SUMMARY AND RECOMMENDATIONS
(1) A positive patch testing has high specificity for specific antibiotic-associated immune-mediated ADRs and appears most useful for DRESS more than AGEP and of lessor utility for FDE, MPE, and SJS/TEN. (2) A negative patch testing does not exclude a drug-specific immune-mediated ADR and should never be used as the sole basis for rechallenge of the implicated antibiotic(s).
Delayed intradermal testing
The use of delayed-IDT (0.02-0.05 ml of highest nonirritating concentration of antimicrobial applied to volar forearm skin, then read at 48-72 h [133] ) is recommended in the investigation of T cell-mediated ADRs [134, 135] . Similar to patch testing, delayed-IDT is limited by the significantly less than 100% The hapten/prohapten model is where an antigen (e.g. antibiotic) covalently binds to a self-peptide, is intracellularly processed and then presented with MHC to T cells as a 'foreign antigen' [51, 52] . An example of the hapten/prohapten model is when penicillin G derivatives bind lysine residues on serum albumin [53] [54] [55] . The p-i concept (the pharmacological interaction with immune receptor) is based upon noncovalent binding of antigens to HLA or T-cell receptor without immune processing, explaining how reactions can occur upon first presentation [51, 56] . The 'altered self-repertoire model' is based upon drug models (e.g. abacavir) that demonstrated that drugs can occupy positions in the peptide-binding groove of the MHC, altering the binding cleft and subsequently the specificity of MHC binding [57] [58] [59] . ADR, adverse drug reaction; HLA, human leukocyte antigen; MHC, major histocompatibility complex. Reproduced with permission from [51] [52] [53] [54] [55] [56] [57] [58] [59] . Table 2 . sensitivity and lack of a suitable positive control [136] . Recommendations for IDT vary regionally and there is a lack of evidence-based volumes and reagents (b-lactam versus non-b-lactam) [121, [133] [134] [135] . IDT has predominately been utilized for b-lactam antimicrobials, especially penicillins more than cephalosporins, in patients with a history of non-SJS/ TEN T cell-mediated ADR [122, 123, 137] . A positive result involves dermal induration/erythema at injection site, which will significantly exceed 5 mm from baseline, 24-72 h after testing. Although extension of the local dermal response at the skin testing site is uncommon, IDT is generally not recommended for the assessment of SJS/TEN [123, 138] , because of risk of systemic events. Adverse reactions following delayed IDT for non-SJS/TEN ADRs are rarely reported [139] [140] [141] , primarily occur in the setting of immediate testing [142] [143] [144] and are often related to errors in concentrations and/or volumes used. Alternative guidelines do not specify the same 'contraindications' to IDT, however, suggest performing IDT only after a negative patch testing [145] . Although it appears patch testing is preferred over IDT for FDE [118] , the sensitivity of IDT for other T cell-mediated ADRs appears higher than that observed with patch testing [64, 130, 141, 146, 147] . In a study of patients with suspected reactions to b-lactams (n ¼ 235 MPE), 7% (18/235) had a positive delayed-IDT, whereas 8.5% (20/235) with negative IDT demonstrated a positive result with oral challenge [147] . IDT has also been used less frequently for other antimicrobials associated with immunemediated ADRs, such as metronidazole [148] . Limitations include only antimicrobials in a commercially available and sterile injectable form can be utilized, short-lived local histamine release (e.g., ciprofloxacin and vancomycin) and irritation (e.g., flucloxacillin) of some products, and overall low NPV. The sensitivity of delayed-IDT from a mixture of small studies has been reported as 6.6-36.3% for MPE (higher with penicillins more than cephalosporins) [149] [150] [151] and 64-100% for DRESS [113, 137] .
Summary of antimicrobial associated T cell-mediated adverse drug reactions

SUMMARY AND RECOMMENDATIONS
(1) Delayed-IDT can be employed as a first-line investigation for non-SJS/TEN immune-mediated ADRs, although the highest nonirritating concentrations for delayed testing have not been validated for most drugs.
(2) A positive delayed-IDT result is highly suggestive of an immune-mediated ADR, but a negative delayed IDT does not exclude an immunemediated ADR and should never be used as the sole basis for rechallenge.
Direct oral challenge
Since first-stage tests such as patch testing and IDT do not have 100% NPVs, oral challenge is contraindicated in certain SCARs (e.g., SJS/TEN/DRESS) [8, 152] and AHS. Oral challenge is required to confirm immune-mediated ADRs following negative delayed-IDT or patch testing in the remaining phenotypes [150,153 && ]. For the investigation of delayed reactions, a prolonged oral challenge (5-7 versus 3 days) increases sensitivity [150, 154] 158] . This is particularly true in children where viral infections or drug-infection interactions are prevalent. Direct oral rechallenge in a cohort of patients with a history of MPE demonstrated only a 6.9% adverse event rate (compared with 3.5% prior) [159 & ]. A direct 5-day oral rechallenge in 119 pediatric patients with mild antibiotic-associated MPE elicited a 5.4% positive response rate, but no serious reactions occurred [80] . The safety of oral rechallenge for antiretroviral immune-mediated ADRs has not been established, but guidelines advise that patients with mild to moderate rash without constitutional symptoms can continue antiretrovirals with close clinical monitoring. In these cases, symptoms should be managed with antihistamines and topical corticosteroids. Physicians commonly 'treat through' mild ADRs to nonnucleoside reverse transcriptase inhibitors (NNRTIs) such as nevirapine or efavirenz, hepatitis C drugs such as telaprevir and antibiotics such as b-lactams and sulfa antimicrobials [160, 161] . Desensitization protocols exist for hypersensitivity reactions to the antiretrovirals tipranavir [162] , amprenavir [163] , darunavir [164] , efavirenz [165] , and have been tried with nevirapine [166] .
RECOMMENDATIONS
(1) Direct oral challenge for 5-7 days should be employed after a negative patch testing or delayed-IDT in the setting of mild to moderate antibiotic skin rashes without evidence of fever, mucosal involvement, malaise, or internal organ involvement.
(2) Oral challenge with a suspected drug should never be employed in the setting of SJS/TEN or DRESS. (3) Ideally, an observed oral or ingestion challenge in the setting of required antibiotic therapy should be employed following negative IDT/ patch testing and knowledge of antibiotic crossreactivity (Table 3) . [79, 152, [167] [168] [169] [170] [171] [172] [173] [174] (4) In acute settings, of mild to moderate rash without fever, mucosal or internal organ involvement, antimicrobials can be continued with close monitoring.
T-CELL DIAGNOSTICS
Lymphocyte transformation test
Ex-vivo investigations have been explored for T cellmediated ADRs, including the lymphocyte transformation test (LTT). LTT has a reported sensitivity of 27-70% and specificity of 72.7-100%, but, remains hindered by testing time, requirement for radioactive materials, and potential dependence on B-cell proliferation [8, [175] [176] [177] . LTT has been used for causality assessments in ceftriaxone, ampicillin/ sulbactam, and metronidazole-associated linear IgA disease, ceftriaxone-associated MPE, penicillin/ amoxicillin-induced MPE, and ceftazidine-induced DRESS [178] [179] [180] [181] . In a small study of amoxicillininduced immune-mediated ADR, correlation between positive in-vivo IDT and LTT was not demonstrated [182] . LTT has also been used in a small number of other case reports/series for immunemediated ADRs secondary to antituberculosis therapies [129] , aminopenicillins [122, 123, 177] , cephalosporins [183] , and antistaphylococcal penicillins [137] .
RECOMMENDATION
(1) Antibiotic LTT is an unvalidated test that has been associated with both false positive and false negative results and currently remains a research tool used in specialized centers for the investigation of T cell-mediated ADRs.
Enzyme-linked immunospot assay
Enzyme-linked immunospot (ELISpot) is an ex-vivo technique used to analyze low-frequency antigenspecific, cytokine-producing (e.g., IFNg) cells in peripheral blood following exposure to pharmacological drug concentrations [8] . ELISpot can be employed for a range of cytokine responses depending on the underlying drug hypersensitivity immunopathogenesis. For example, AGEP can have high IL-13 and IFNg, FDE raises IL-10, whereas DRESS can have high IL-5 or IFNg [60, 184] . ELISpots measuring granzyme have also been employed [175] . ELISpot studies have demonstrated that 1 : 150 to 1 : 5000 T cells remain 'reactive' in patients after ADR for up to 12-20 years [60, 185] . ELISpot has also been shown to have better sensitivity than LTT in detecting drugspecific T-cell responses [185, 186] . Nonetheless, ELI-Spot has only been employed in research settings for the investigation of antimicrobial allergy. Estimations of sensitivity and specificity are flawed because of the absence of a reference gold standard. However, increasing the drug concentration used to stimulate the patients' cells and increasing incubation periods (48 h versus overnight) have been shown to increase assay sensitivity without decreasing specificity. An examination of ELISpot use in antimicrobial T cell-mediated ADRs is outlined below.
ENZYME-LINKED IMMUNOSPOT AND ANTIVIRAL IMMUNE-MEDIATED ADVERSE DRUG REACTIONS
ELISpot is described in studies examining antiretroviral hypersensitivity reactions, notably abacavir and nevirapine. ELISpot has been used to detect abacavir hypersensitivity in patients that are HLA-B Ã 57:01 negative [187] . IFNg ELISpot has also been used to demonstrate that abacavir unexposed HLA-B 
ENZYME-LINKED IMMUNOSPOT AND ANTIBIOTIC IMMUNE-MEDIATED ADVERSE DRUG REACTIONS
Penicillins
Earlier studies demonstrate that ELISpot IFNg testing was positive in patients with a history of amoxicillin immune-mediated ADRs [185, 190] . No positive ELISpot results were identified in control patients or those with a history of IgE-mediated disease, highlighting the specificity of the test. The intensity of response was, however, proportional to time after diagnosis. The overall sensitivity and specificity was 91 and 95%, respectively. Khalil et al. [190] demonstrated a sensitivity and specificity of 80 and 100%, respectively for ELISpot measuring IL-2, IL-5, and IFNg in patients with amoxicillin immune-mediated ADR. Rozieres et al. [185] demonstrated ex-vivo effectiveness for other b-lactams, including ticarcillin [191] . ELISpot has also been used in models using antigen-specific Tcell clones to confirm patients with a history to piperacillin hypersensitivity [192] .
Cephalosporins
Tanvarasethee et al. [193] examined the use of ELI-Spot to diagnose cephalosporin-induced MPE and compare against SPT, delayed-IDT, and patch testing. From the 25 patients, 40% had a positive IFNg and IL-5 response compared with 8% who had a positive delayed-IDT or patch testing (P ¼ 0.008). There was a higher probability of positive ELISpot if performed within 2 years of reaction (P ¼ 0.046) [193] .
Other antimicrobials
The use of ELISpot for quinolones, glycopeptides, TMP-SMX, and other commonly used antibacterial therapy is absent. Aminoglycosides are an infrequent cause of SCARs, yet a case of amikacininduced DRESS was confirmed on patch testing and ELISpot [194] . A case of sulfasalazine hypersensitivity syndrome was also confirmed with ELI-Spot [195] . The use in other antimicrobials is also illdefined. Further research is required to evaluate this testing in a range of antimicrobial therapies.
RECOMMENDATION
(1) ELISpot remains a test available only in specialized centers for the investigation of T cellmediated ADRs.
PREDICTING T-CELL RESPONSES: HUMAN LEUKOCYTE ANTIGEN TYPING
Recently, an increasing number of antimicrobial immune-mediated ADRs have been associated with various HLA alleles (Table 4 ). In general, because of varying HLA allele frequencies, different ethnic populations have different genetic associations. To date, the best characterized antimicrobial-induced, HLA-associated immune-mediated ADRs that appear to generalize across populations include AHS and nevirapine SCARs. The association between AHS and HLA-B Ã 57:01 resulted in the implementation of a routine screening test that is widely employed in the developed world before abacavir treatment. Before widespread acceptance, the HLA-B Ã 57:01 genetic association with abacavir was established in a large population with a diverse genetic background. This screening test has a positive predictive value of 55% and a NPV of 100%, which is crucial for drug safety [218] [219] [220] . Less than 100% NPVs and very low positive predictive values of other antimicrobial drug hypersensitivity HLA associations have limited their translation into routine clinical practice as screening tests. For example, although only 13 individuals would need to be screened for HLA-B Ã 57:01 to prevent a single case of AHS, over 14 000 individuals would have to be tested for this same allele to prevent a single case of flucloxacillin-associated hepatitis. The story of nevirapine-induced immune-mediated ADRs is quite complex. Nevirapine-induced immune-mediated ADRs have been associated with different HLA alleles across different ethnic populations. These HLA associations appear to be phenotype specific and involve both class I and class II HLA alleles. An association between nevirapineinduced hepatitis and HLA-DRB1 Ã 01:01 was first reported in a Western Australian population [217] and has since been reported in other Caucasian populations [216] . The closely related allele HLA-DRB1 Ã 01:02 was associated with nevirapine-induced hepatitis in a South African cohort [196] . Nevirapine DRESS has been associated with the HLA-Cw Ã 8 or [212] [213] [214] [215] . Many of these alleles including HLA-DRB Ã 01, HLA-Cw Ã 04 and HLA-B Ã 35:05 are also associated with nevirapine-induced rash [209] [210] [211] 215, 216] .
Other HLA associations have been described for immune-mediated ADRs to efavirenz, dapsone, flucloxacillin, amoxicillin-clavulanante, sulfamethoxazole, aminopenicillins, sulfonamides, isoniazid, and levamisole (Table 4) .
Many of these antimicrobials such as flucoxacillin and amoxicillin-clavulanate are specifically associated with drug-induced liver injury, which can be associated with fulminant hepatic failure [220] . Although few HLA screening tests have advanced to the level of routine clinical practice, HLA associations have significantly advanced our understanding of the immunopathogenesis of immune-mediated ADRs.
RECOMMENDATION
(1) Level IA evidence exists to support screening for HLA-B Ã 57:01 prior to initiation of abacavir therapy. This screening test has a 100% NPV and is widely recommended as part of guidelinebased practice.
CROSS REACTIVITY IN T CELL-MEDIATED REACTIONS
In settings where in-vivo and ex-vivo diagnostics are unavailable, understanding cross-reactivity based on shared chemical structure among antimicrobials is essential (Table 3) . Most of the rates of crossreactivity for delayed immune-mediated ADRs are extrapolated from data that exist for cross-reactivity in the setting of immediate hypersensitivities. Earlier reports of high rates of penicillin/cephalosporin cross-reactivity were confounded by penicillin contamination of cephalosporin manufacturing [2, 3, 222] . Current literature supports that most cross-reactivity that occurs in the b-lactam class occurs on the basis of shared R1 and/or R2 side chains [85, 149, 150] . Recent reports suggest patients with a history of delayed hypersensitivity to aminopenicillins most commonly cross-react with aminocephalosporins sharing an R1 group such as cephalexin, cefaclor, and cephadroxil and generally tolerate all other cephalosporins [223, 224] . Challenging patients with a penicillin/amoxicillin allergy history with a cephalosporin not sharing the same side chain (e.g., cefuroxime or ceftriaxone) proved successful in a study of 41 patients by Novalbas et al. [225] . The rate of cross-reactivity between penicillin and third-generation cephalosporins now approaches 1%, a far cry from 10-25% initially quoted in very early studies [226] . Romano et al. [169] demonstrated that patients with cephalosporin immediate hypersensitivity can still be safely treated with compounds that have side-chain determinants different from those of the responsible cephalosporin.
Cross-reactivity between carbapenems has been infrequently reported [227] ; a shared T-cell epitope remains unknown [227] . Cross-reactivity between macrolides also appears rare, with infrequent reports of immediate cross-reactivity noted particularly between those with 14-membered ring such as erythromycin, clarithromycin, and roxithromycin and the 15-membered azalide, azithromycin [228] . T cell-mediated cross-reactivity between tetracyclines [229] , in particular doxycycline and minocycline has been reported [229] . Cross-reactivity [230] and tolerance [231] have been reported for aminoglycoside antibiotics in which ADRs are more common for topical than systemic agents because of contact sensitization [194, 232] . For nitroimidazoles (e.g., metronidazole, tindazole) T cell-mediated ADRs have been reported, with cross-reactivity noted [94] [95] [96] 233] .
Delayed immune-mediated ADRs are less frequent than immediate ADRs in regards to quinolones [234] , with cross-reactivity more commonly occurring between first and second-generation quinolones than third and fourth generation [234] [235] [236] [237] . Glycopeptide (vancomycin and teicoplanin) cross-reactivity is also reported [238] [239] [240] , but remains controversial, with many reports extrapolated from reoccurrence of hematological disturbances. Patients with isolated vancomycin hypersensitivity have also been known to tolerate teicoplanin [97, 238, [241] [242] [243] .
An estimated 3-6% of the population is considered 'allergic' to sulfonamides, with TMP/SMX the most commonly implicated example [244] . Although belief in overall sulfonamide crossreactivity persists [245] , recent reviews do not support cross-reactivity between antibacterial and nonantibacterial sulfonamides [244, [246] [247] [248] [249] . There is cross-reactivity between antibiotic sulfonamides, especially sulfasalazine and sulfamethoxazole [250] . The nonantibacterial sulfonamides (e.g., azetazolamide, forusemide, celecoxib, thiazide diuretics, sumatriptan, sotalol, probenacid) do not contain the structural region known to cause the allergic response (i.e., N1 heterocyclic ring; an N-containing ring attached to the N1 nitrogen of the sulfonamide group and arylamine group at the N4 position). Although early reports questioned the potential for cross-reactivity between TMP-SMX and darunavir [249, 251, 252] , authors have noted an absence of TMP-SMX allergy history in those with darunavir hypersensitivity [253] [254] [255] . Notably patients with a history of sulfa antimicrobial allergy were not excluded from darunavir clinical trials.
The potential for cross-reactivity between dapsone and TMP-SMX is now somewhat controversial with most reports occurring in HIV-infected individuals without evidence of positive rechallenge. The current estimated rate of cross-reactivity is less than previously reported (9-11% versus 20-45%) [256, 257] . In those requiring TMP-SMX therapy with a history of non-SCAR ADR to antibacterial sulfonamide, we recommend a supervised oral rechallenge, rather than drug avoidance [258, 259] .
Antiretroviral
Cross-reactivity between most antiretroviral classes is likely very low because of the lack of structural similarities. However, patients with prior severe hypersensitivity to an NNRTI should be monitored if new NNRTI therapy is initiated. Mehta and Maartens [260] reported recurrent reactions in 12.6% of patients with reported rash who were switched from nevirapine to efavirenz, compared with 50% of patients switched from efavirenz to nevirapine. Cross-reactivity is reported to be higher between nevirapine and delavirdine, which have a similar structure, but delavirdine is not currently used because of its difficult dosing, pill burden, drug interactions, and lower efficacy compared with contemporary NNRTIs [261] .
Recommendations for antimicrobial use, in relation to likely cross-reactivity, in patients with delayed hypersensitivities to isolate antimicrobials are given in Table 3 .
CONCLUSION
In an era of increasing antimicrobial resistance and use of broad-spectrum antimicrobial therapy, ensuring patients are correctly 'labeled' in respect to antimicrobial-associated immune-mediated ADRs is essential. Reexposure to the implicated antimicrobial, especially in the setting of SCARs and AHS, is associated with significant morbidity and mortality.
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